Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
As clinics struggle with shortages and manufacturers warn of supply limits extending well into 2025 and 2026, the demand for easier, faster or cheaper alternatives has exploded
Their ability to reduce MACE (major adverse cardiovascular events) gives them a unique advantage over older therapies
My view is that the pronounced effect of GLP-1 analogues on gastric emptying is not only an important mediator of satiety and reduced food intake but also a likely mechanism responsible for its effect on type 2 diabetes and cardiovascular disease
Luyu Amber Xie, Ph.D., Pharm.D., Assistant Professor of Health Data Science and Biostatistics in the ODonnell School of Public Health and co-Director of the Biostatistics and Data Science Core
GLP-1, or glucagon-like peptide-1, is a hormone secreted in the gut when you eat